| bivalirudin versus heparin + GP2b3a inhibitors | |||
| ACUITY (sub groups PCI, bivalirudin alone) importé, 2007 | bivalirudin alone versus heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors | patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography (sub group). | open Follow-up duration: 30 days |
| bivalirudin + GP2b3a inhibitors versus heparin + GP2b3a inhibitors | |||
| ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007 | bivalirudin +
versus heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors | patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography. | open Follow-up duration: 30 days |
| clopidogrel versus placebo | |||
| CURE (PCI sub study), 2001 | pretreatment with clopidogrel -+aspirin 75–325 mg) versus placebo (+ aspirin 75–325 mg) | patients with non-ST-elevation acute coronary syndrome undergoing PCI | double blind |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
